Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Nov 22;11(11):CD005342.
doi: 10.1002/14651858.CD005342.pub4.

Adjuvant platinum-based chemotherapy for early stage cervical cancer

Frederico S Falcetta  1 , Lídia Rf Medeiros, Maria I Edelweiss, Paula R Pohlmann, Airton T Stein, Daniela D Rosa
Affiliations
Meta-Analysis

Adjuvant platinum-based chemotherapy for early stage cervical cancer

Frederico S Falcetta et al. Cochrane Database Syst Rev. .

Abstract

Background: This is the second updated version of the original Cochrane review published in the Cochrane Library 2009, Issue 3. Most women with early cervical cancer (stages I to IIA) are cured with surgery or radiotherapy, or both. We performed this review originally because it was unclear whether cisplatin-based chemotherapy after surgery, radiotherapy or both, in women with early stage disease with risk factors for recurrence, was associated with additional survival benefits or risks.

Objectives: To evaluate the effectiveness and safety of adjuvant platinum-based chemotherapy after radical hysterectomy, radiotherapy, or both in the treatment of early stage cervical cancer.

Search methods: For the original 2009 review, we searched the Cochrane Gynaecological Cancer Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) in the Cochrane Library 2009, Issue 1), MEDLINE, Embase, LILACS, BIOLOGICAL ABSTRACTS and CancerLit, the National Research Register and Clinical Trials register, with no language restriction. We handsearched abstracts of scientific meetings and other relevant publications. We extended the database searches to November 2011 for the first update and to September 2016 for the second update.

Selection criteria: Randomised controlled trials (RCTs) comparing adjuvant cisplatin-based chemotherapy (after radical surgery, radiotherapy or both) with no adjuvant chemotherapy, in women with early stage cervical cancer (stage IA2-IIA) with at least one risk factor for recurrence.

Data collection and analysis: Two review authors extracted data independently. Meta-analysis was performed using a random-effects model, with death and disease progression as outcomes.

Main results: For this second updated version we identified only one small trial reporting grade 4 toxicity results, without disease-free or overall survival data with a median follow-up of 16 months.From the first updated version, we identified three trials that were ongoing, and remain so in 2016.Four trials including 401 women with evaluable results with early cervical cancer were included in the meta-analyses. The median follow-up period in these trials ranged from 29 to 42 months. All women had undergone surgery first. Three trials compared chemotherapy combined with radiotherapy versus radiotherapy alone; and one trial compared chemotherapy followed by radiotherapy versus radiotherapy alone. It was not possible to perform subgroup analyses by stage or tumour size.Compared with adjuvant radiotherapy, chemotherapy combined with radiotherapy significantly reduced the risk of death (two trials, 297 women; hazard ratio (HR) = 0.56, 95% confidence interval (CI): 0.36 to 0.87) and disease progression (two trials, 297 women; HR = 0.47, 95% CI 0.30 to 0.74), with no heterogeneity between trials (I² = 0% for both meta-analyses). Acute grade 4 toxicity occurred significantly more frequently in the chemotherapy plus radiotherapy group than in the radiotherapy group (three trials, 321 women; risk ratio (RR) 6.26, 95% CI 2.50 to 15.67). We considered the evidence for all three outcomes to be of a moderate quality, using the GRADE approach due to small numbers and limited follow-up in the included studies. In addition, it was not possible to separate data for bulky early stage disease.In the one small trial that compared adjuvant chemotherapy followed by radiotherapy with adjuvant radiotherapy alone there was no difference in disease recurrence between the groups (one trial, 71 women; HR = 1.34; 95% CI 0.24 to 7.66) and overall survival was not reported. We considered this evidence to be of a low quality.No trials compared adjuvant platinum-based chemotherapy with no adjuvant chemotherapy after surgery for early cervical cancer with risk factors for recurrence.

Authors' conclusions: The addition of platinum-based chemotherapy to adjuvant radiotherapy (chemoradiation) may improve survival in women with early stage cervical cancer (IA2-IIA) and risk factors for recurrence. Adjuvant chemoradiation is associated with an increased risk of severe acute toxicity, although it is not clear whether this toxicity is significant in the long term due to a lack of long-term data. This evidence is limited by the small numbers and low to moderate methodological quality of the included studies. We await the results of three ongoing trials, which are likely to have an important impact on our confidence in this evidence.

PubMed Disclaimer

Conflict of interest statement

None to declare.

Figures

1
1
Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
2
2
Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
1.1
1.1. Analysis
Comparison 1: Radiotherapy plus chemotherapy versus radiotherapy, Outcome 1: Death from all causes
1.2
1.2. Analysis
Comparison 1: Radiotherapy plus chemotherapy versus radiotherapy, Outcome 2: Disease progression
1.3
1.3. Analysis
Comparison 1: Radiotherapy plus chemotherapy versus radiotherapy, Outcome 3: Grade 4 toxicity
2.1
2.1. Analysis
Comparison 2: Chemotherapy followed by radiotherapy versus radiotherapy, Outcome 1: Disease progression
See this image and copyright information in PMC

Update of

References

References to studies included in this review

Peters 2000 {published data only}
    1. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. Journal of Clinical Oncology 2000;18(8):1606-13. [PMID: 10764420] - PubMed
Protocol CE3005 {unpublished data only}
    1. Cancer Research UK. A prospective randomised trial of adjuvant chemotherapy in node positive early stage carcinoma of the cervix - Protocol CE3005. UK Clinical Trials Register 2001.
Sun 2015 {published data only}
    1. Sun W, Wang T, Shi F, Wang J, Hui B, Zhang Y, et al. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy. BMC Cancer 2015;15:353. - PMC - PubMed
Tattersall 1992 {published data only}
    1. Tattersall MH, Ramirez C, Coppleson M. A randomized trial of adjuvant chemotherapy after radical hysterectomy in stage Ib-IIa cervical cancer patients with pelvic lymph node metastases. Gynecologic Oncology 1992;46(2):176-81. [PMID: 1500019] - PubMed

References to studies excluded from this review

Argenta 2006 {published data only}
    1. Argenta PA, Ghebre R, Dusenbery KE, Chen MD, Judson PL, Downs LS, et al. Radiation therapy with concomitant and adjuvant cisplatin and paclitaxel in high-risk cervical cancer: long-term follow-up. European Journal of Gynaecological Oncology 2006;27(3):231-5. [PMID: 16800247] - PubMed
Blohmer 2001 {published data only}
    1. Blohmer JU, Paepke S, Bohmer D, Ernhardt B, Sehouli J, Elling D, et al. Adjuvant chemotherapy of cervix carcinoma--results of a phase II study. Zentralblatt fur Gynakologie 2001;123(5):286-91. - PubMed
Buxton 1990 {published data only}
    1. Buxton EJ, Saunders N, Blackledge GR, Kelly K, Redman CW, Monaghan J, et al. The potential for adjuvant therapy in early-stage cervical cancer. Cancer Chemotherapy and Pharmacology 1990;26(Suppl 26):S17-21. [PMID: 1693315] - PubMed
Chatterjee 2013 {published data only}
    1. Chatterjee K, Mondal SK, Sarkar P. Adjuvant chemotherapy in the management of cervical cancers - A prospective randomized study. In: European Journal of Cancer. Conference: European Cancer Congress 2013, ECC 2013 Amsterdam Netherlands edition. Vol. 49. 2013:S721-S722.
Curtin 1996 {published data only}
    1. Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, et al. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecologic Oncology 1996;61:3-10. [PMID: 8626113] - PubMed
Dimpfl 1996 {published data only}
    1. Dimpfl T, Stumpfe M, Baltzer J, Genz T. Results of adjuvant chemotherapy of operated high risk cervix carcinoma. Geburtshilfe Frauenheilkd 1996;56(10):517-9. [PMID: 9036063] - PubMed
Frigerio 1994 {published data only}
    1. Frigerio L, Busci L, Rabaiotti E, Mariani A. Adjunctive radiotherapy after radical hysterectomy in high risk early stage cervical carcinoma. Assessment of morbidity and recurrences. European Journal of Gynaecological Oncology 1994;15(2):132-7. [PMID: 8005143] - PubMed
Hansgen 2001 {published data only}
    1. Hansgen G, Dunst J. Adjuvant radio- and chemotherapy in cervix carcinoma. Zentralblatt fur Gynakologie 2001;123(5):280-5. [PMID: 11449621] - PubMed
Hansgen 2002 {published data only}
    1. Hansgen G, Kuhnt T, Pigorsch S, Strauss H, Dunst J. Adjuvant simultaneous radiochemotherapy after operated uterine cervix carcinoma in high risk situation. Results of a pilot study. Strahlentherapie und Onkologie 2002;178(2):71-7. [PMID: 11942040] - PubMed
Harrand 2013 {published data only}
    1. Harrand R, Sadozye AH, Siddiqui N, Burton K, Shanbhag S, Davis J, et al. Audit of adjuvant cisplatin +/-vaginal brachytherapy following radical hysterectomy and nodal dissection for cervical cancer. In: International Journal of Gynecological Cancer. 18th International Meeting of the European Society of Gynaecological Oncology, ESGO 2013 Liverpool United Kingdom edition. Vol. 23. 2013:231.
Ikeda 1994 {published data only}
    1. Ikeda M, Teshima K, Noda K, Yamagata S, Sugawa T, Okamura S, et al. Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association. Gan To Kagaku Ryoho 1994;21(12):1967-74. - PubMed
Iwasaka 1998 {published data only}
    1. Iwasaka T, Kamura T, Yokoyama M, Matsuo N, Nakano H, Sugimori H. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma: a comparison with effects of adjuvant radiotherapy. Obstetrics and Gynecology 1998;91(6):977-81. [PMID: 9611008] - PubMed
Kato 1994 {published data only}
    1. Kato T, Yakushiji M, Yamabe T, Sugimori H, Hidaki T, Tsukamoto N, et al. A multicenter cooperative study on supplementary chemotherapy of uterocervical cancer. The Kyushu UFT Study Group of Uterocervical Cancer. Gan To Kagaku Ryoho 1994;21(8):1221-7. - PubMed
Kemnitz 1991 {published data only}
    1. Kemnitz T, Krafft W, Glaser F, Schirmer A. Efficacy of adjuvant chemotherapy in metastasizing cervix carcinoma. A pilot study. Zentralblatt fur Gynakologie 1991;113(13):777-81. [PMID: 1927129] - PubMed
Killackey 1993 {published data only}
    1. Killackey MA, Boardman L, Carroll DS. Adjuvant chemotherapy and radiation in patients with poor prognostic stage Ib/IIa cervical cancer. Gynecologic Oncology 1993;49(3):377-9. [PMID: 8314541] - PubMed
Kim 2007 {published data only}
    1. Kim YB, Cho JH, Keum KC, Lee CG, Seong J, Suh CO, et al. on current chemoradiotherapy followed by adjuvant chemotherapy in uterine cervical cancer patients with high-risk factors. Gynecologic Oncology 2007;104(1):58-63. [PMID: 16919718] - PubMed
Koh 2000 {published data only}
    1. Koh WJ, Panwala K, Greer B. Adjuvant therapy for high-risk, early stage cervical cancer. Seminars in Radiation Oncology 2000;10(1):51-60. [PMID: 10671659] - PubMed
Lahousen 1990 {published data only}
    1. Lahousen M, Haas J. Adjuvant chemotherapy in radical surgery of cervix cancer. Zentralblatt fur Gynakologie 1990;112(11):707-13. [PMID: 2399774] - PubMed
Lahousen 1999 {published data only}
    1. Lahousen M, Haas J, Pickel H, Hackl A, Kurz C, Ogris H, et al. Chemotherapy versus radiotherapy versus observation for high-risk cervical carcinoma after radical hysterectomy: A randomized, prospective, multicenter trial. Gynecologic Oncology 1999;73(2):196-201. [PMID: 10329034] - PubMed
Lai 1989 {published data only}
    1. Lai CH, Lin TS, Soong YK, Chen HF. Adjuvant chemotherapy after radical hysterectomy for cervical carcinoma. Gynecologic Oncology 1989;35(2):193-8. [PMID: 2478428] - PubMed
Lai 1998 {published data only}
    1. Lai CH, Tang SG, Chang TC, Tseng CJ, Chou HH, Huang KG, et al. Implications of a failed prospective trial of adjuvant therapy after radical hysterectomy for stage Ib-IIa cervical carcinoma with pelvic node metastases. Changgeng Yi Xue Za Zhi 1998;21(3):291-9. [PMID: 9849010] - PubMed
Lai 1999 {published data only}
    1. Lai CH, Hong JH, Hsueh S, Ng KK, Chang TC, Tseng CJ, et al. Preoperative prognostic variables and the impact of postoperative adjuvant therapy on the outcomes of Stage IB or II cervical carcinoma patients with or without pelvic lymph node metastases: an analysis of 891 cases. Cancer 1999;85(7):1537-46. - PubMed
Lee 2013 {published data only}
    1. Lee TS, Kang SB, Kim YT, Park BJ, Kim YM, Lee JM, et al. Chemoradiation with paclitaxel and carboplatin in high-risk cervical cancer patients after radical hysterectomy: a Korean Gynecologic Oncology Group study. International Journal of Radiation Oncology, Biology, Physics 2013;86(2):304-10. - PubMed
Lin 1998 {published data only}
    1. Lin H, ChangChien CC, Chang SY, Leung SW. Survival advantages and complications of adjuvant therapy in early-stage cervical cancer with pelvic node metastasis. Changgeng Yi Xue Za Zhi 1998;21(4):383-90. - PubMed
Lin 2000 {published data only}
    1. Lin H, ChangChien CC, Huang EY, Eng HL, Huang CC. The role of radical surgery followed by adjuvant therapy for high-risk early-stage cervical carcinoma patients with pelvic lymph node metastasis. European Journal of Obstetrics, Gynecology and Reproductive Biology 2000;93(1):85-90. [MEDLINE: PMID: 11000510] - PubMed
Linghu 2003 {published data only}
    1. Linghu H, Xu XR, Mei YY, Tang JY, Tang LD, Sun T. Short-time analysis for adjuvant chemotherapy in patients with early- stage bulky cervical carcinoma. Chinese Journal for Cancer Research 2003;15(2):144-8. [Embase]
Liu 2014 {published data only}
    1. Liu J, Huang H, Li JD, Li YF, Huang X, Zhang YN, et al. Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma-interim analysis of a 3-arm randomized control study. In: International Journal of Gynecological Cancer. Conference: 15th Biennial Meeting of the International Gynecologic Cancer Society Melbourne, VIC Australia edition. Vol. 24 (Supplement 4). 2014:7-8.
Lu 2000 {published data only}
    1. Lu KH, Burke TW. Early cervical cancer. Current Treatment Options in Oncology 2000;1(2):147-55. [PMID: 12057052] - PubMed
McCaffrey 2011 {published data only}
    1. McCaffrey R, Bahtiyar M, Kohorn EI, Chambers JT, Schwartz PE, Chambers SK. Neoadjuvant and adjuvant chemotherapy of cervical cancer: Mature results of the phase 2 PBM-PFU protocol. International Journal of Gynecological Cancer 2011;21:535-44. - PubMed
Morris 1999 {published data only}
    1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. New England Journal of Medicine 1999;340(15):1137-43. [PMID: 10202164] - PubMed
Morton 1996 {published data only}
    1. Morton GC, Thomas GM. Does adjuvant chemotherapy change the prognosis of cervical cancer? Current Opinions in Obstetrics and Gynecology 1996;8(1):17-20. [MEDLINE: PMID: 8777252] - PubMed
Mossa 2003 {published data only}
    1. Mossa B, Framarino ML, Napolitano C, Marziani R, Imperato F, Marzetti L. Does adjuvant chemotherapy improve the prognosis of cervical carcinoma with lymph-node metastasis? A long-term follow-up. European Journal of Gynaecologic Oncology 2003;24(1):33-40. [MEDLINE: PMID: 12691314] - PubMed
MRC CE04/EORTC55954 {unpublished data only}
    1. EORTC-55954, COSA, EU-98061, NSGO-CC-9502, MRC-CE04. A randomised phase III study of chemotherapy and radiotherapy vs. radiotherapy alone as adjuvant treatment to patients with node positive stages IB or IIA cervix cancer. http://www.controlled-trials.com/mrct/trial/391321/MRC-CE04.
Nakamura 2014 {published data only}
    1. Nakamura K, Satoh T, Takei Y, Nagao S, Sekiguchi I, Suzuki M. Analysis of the effect of adjuvant radiotherapy on outcome and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors. In: Gynecologic Oncology. 45th Annual Meeting on Women's Cancer of the Society of Gynecologic Oncology, SGO 2014 Tampa, FL United States edition. Vol. 133 (Supplement 1). 2014:61-2.
Ng 1995 {published data only}
    1. Ng HT, Yuan CC, Kan YY, Ho ES, Yen MS, Chao KC. An evaluation of chemotherapy in patients with cancer of the cervix and lymph node metastases. Archives of Gynecology and Obstetrics 1995;256(1):1-4. [PMID: 7726648] - PubMed
Park 1997 {published data only}
    1. Park TK. Adjuvant therapy in cervical cancer patients with high risk factors. Yonsei Medical Journal 1997;38(5):255-60. [MEDLINE: ] - PubMed
Park 2001 {published data only}
    1. Park TK, Kim SN, Kwon JY, Mo HJ. Postoperative adjuvant therapy in early invasive cervical cancer patients with histopathologic high-risk factors. International Journal of Gynecological Cancer 2001;11(6):475-82. [PMID: 11906552] - PubMed
Park 2012 {published data only}
    1. Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Kim YS, ET AL. Comparison of outcomes between radical hysterectomy followed by tailored adjuvant therapy versus primary chemoradiation therapy in IB2 and IIA2 cervical cancer. Journal of Gynecologic Oncology 2012;23(4):226-34. - PMC - PubMed
Pu 2013 {published data only}
    1. Pu J, Qin SS, Ding JX, Zhang Y, Yu CH, Li T, et al. A randomized controlled study of single-agent cisplatin and radiotherapy versus docetaxel/cisplatin and radiotherapy in high-risk early-stage cervical cancer after radical surgery. Journal of Cancer Research and Clinical Oncology 2013;139(4):703-8. - PMC - PubMed
Richter 1982 {published data only}
    1. Richter P. About the value of adjuvant chemotherapy in advanced cervical cancer. First results of a prospective randomised study (author's transl). Archiv für Geschwulstforschung 1982;52(2):117-22. [PMID: 7049112] - PubMed
Rogers 2012 {published data only}
    1. Rogers L, Siu SS, Luesley D, Bryant A, Dickinson HO. Radiotherapy and chemoradiation after surgery for early cervical cancer. Cochrane Database of Systematic Reviews 2012, Issue 5. Art. No: CD007583. [DOI: 10.1002/14651858.CD007583.pub3] - DOI - PMC - PubMed
Roth 1994 {published data only}
    1. Roth SL, Nitz U, Mosny D. The value of adjuvant radio- or chemotherapy after primary surgical therapy of cervix cancer. 1. Adjuvant radiotherapy of cervix cancer. Gynakologe 1994;27(2):89-95. [PMID: 8039748] - PubMed
Rushdan 2004 {published data only}
    1. Rushdan MN, Tay EH, Khoo-Tan HS, Lee KM, Low JH, Ho TH, et al. Tailoring the field and indication of adjuvant pelvic radiation for patients with FIGO stage Ib lymph nodes-negative cervical carcinoma following radical surgery based on the GOG score - A pilot study. Annals of the Academy of Medicine, Singapore 2004;33(4):467-72. [15329758] - PubMed
Russel 1995 {published data only}
    1. Russell AH. Adjuvant postoperative radiation: what size target? Gynecologic Oncology 1995;58(1):1-3. [PMID: 7789872] - PubMed
Ryu 2005 {published data only}
    1. Ryu HS, Chun M, Chang KH, Chang HJ, Lee JP. Postoperative adjuvant concurrent chemoradiotherapy improves survival rates for high-risk, early stage cervical cancer patients. Gynecologic Oncology 2005;96(2):490-5. [PMID: 15661240] - PubMed
Schwarz 2011 {published data only}
    1. Schwarz JK, Wahab S, Grigsby PW. Prospective phase I-II trial of helical tomotherapy with or without chemotherapy for postoperative cervical cancer patients. International Journal of Radiation Oncology, Biology, Physics 2011;81(5):1258-63. - PubMed
Sehouli 2012 {published data only}
    1. Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, et al. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Annals of Oncology 2012;23(9):2259-64. - PubMed
Shimizu 1995 {published data only}
    1. Shimizu Y. Chemotherapy in the management of advanced or high risk cervical cancer. Gan To Kagaku Ryoho 1995;22(9):1152-62. [MEDLINE: PMID: 7661566] - PubMed
Shu 2015 {published data only}
    1. Shu P, Shen Y, Zhao Y, Xu F, Qiu M, Li Q, et al. A phase I study of adjuvant intensity-modulated radiotherapy with concurrent paclitaxel and cisplatin for cervical cancer patients with high risk factors. Medical Oncology 2015;32(11):247. - PubMed
Sivanesaratnam 1987 {published data only}
    1. Sivanesaratnam V, Sen DK, Jayalakshmi P. Adjuvant cytotoxic chemotherapy following Wertheim radical hysterectomy for cervical cancer. Australian and New Zealand Journal of Obstetrics and Gynaecology 1987;27(3):231-3. [PMID: 2449159] - PubMed
Sivanesaratnam 1989 {published data only}
    1. Sivanesaratnam V, Jayalakshmi P. Mitomycin C adjuvant chemotherapy after Wertheim's hysterectomy for stage IB cervical cancer. Cancer 1989;64(4):798-800. [PMID: 2501019] - PubMed
Sivanesaratnam 1998 {published data only}
    1. Sivanesaratnam V. Adjuvant chemotherapy in "high risk" patients after Wertheim hysterectomy -10-year survivals. Annals Academy of Medicine Singapore 1998;27(5):622-6. [PMID: 9919328] - PubMed
Strauss 2002 {published data only}
    1. Strauss HG, Kuhnt T, Laban C, Puschmann D, Pigorsch S, Dunst J, et al. Chemoradiation in cervical cancer with cisplatin and high-dose rate brachytherapy combined with external beam radiotherapy. Results of a phase-II study. Strahlentherapie und OnkologieStrahlenther Onkol 2002;178(7):378-85. [PMID: 12163992] - PubMed
Wada 1995 {published data only}
    1. Wada K, Koyama M, Iijima Y, Inagaki M, Hirota Y, Hongo J, et al. Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer. Nippon Sanka Fujinka Gakkai Zasshi 1995;47(3):244-8. - PubMed
Wang 2015 {published data only}
    1. Wang X, Shen Y, Zhao Y, Li Z, Gou H, Cao D, et al. Adjuvant intensity-modulated radiotherapy (IMRT) with concurrent paclitaxel and cisplatin in cervical cancer patients with high risk factors: A phase II trial. European Journal of Surgical Oncology 2015;41(8):1082-8. - PubMed
Watanabe 2006 {published data only}
    1. Watanabe Y, Nakai H, Shimaoka M, Tobiume T, Tsuji I, Hoshiai H. Feasibility of concurrent cisplatin use during primary and adjuvant chemoradiation therapy: a phase I study in Japanese patients with cancer of the uterine cervix. International Journal of Clinical Oncology 2006;11(4):309-13. [PMID: 16937305] - PubMed
Wen 2013 {published data only}
    1. Wen H, Liu T. Treatment results of adjuvant chemotherapy for patients with intermediate-risk cervical cancer. In: International Journal of Gynecological Cancer. 18th International Meeting of the European Society of Gynaecological Oncology, ESGO 2013 Liverpool United Kingdom edition. Vol. 23. 2013:806.
Wertheim 1985 {published data only}
    1. Wertheim MS, Hakes TB, Doghestani AN, Nori D, Smith DH, Lewis JL Jnr. A pilot study of adjuvant therapy in patients with cervical cancer at high risk of recurrence after radical hysterectomy and pelvic lymphadenectomy. Journal of Clinical Oncology 1985;3(7):912-6. - PubMed
Wolfson 2012 {published data only}
    1. Wolfson AH, Varia MA, Moore D, Rao GG, Gaffney DK, Erickson-Wittmann BA, et al. ACR Appropriateness Criteria role of adjuvant therapy in the management of early stage cervical cancer. Gynecologic Oncology 2012;125(1):256-62. - PubMed
Yamamoto 2004 {published and unpublished data}
    1. Yamamoto K, Izumi R, Hasegawa K, Nakajima H, Ohashi K, Kudo R et, al. Adjuvant oral 5-fluorouracil for cervical cancer: Japanese Gynecologic Oncology Group report. International Journal of Oncology 2004;24(5):1175-9. [PMID: 15067339] - PubMed
Yessaian 2004 {published data only}
    1. Yessaian A, Magistris A, Burger RA, Monk BJ. Radical hysterectomy followed by tailored postoperative therapy in the treatment of stage IB2 cervical cancer: feasibility and indications for adjuvant therapy. Gynecologic Oncology 2004;94(1):61-6. [PMID: 15262120] - PubMed
Yoon 2014 {published data only}
    1. Yoon H, Cha J, Kim G, Chung Y, Kim Y. The long-term follow-up result of extended field radiation therapy for uterine cervical cancer with positive para-aortic lymph nodes: Does the addition of chemotherapy have survival benefit? In: International Journal of Radiation Oncology, Biology, Physics. 56th Annual Meeting of the American Society for Radiation Oncology, ASTRO 2014 San Francisco, CA United States edition. Vol. 90. 2014:S479.
Zanetta 1995 {published data only}
    1. Zanetta G, Colombo A, Milani R, Placa F, Mangioni C. Long-term results of sequential postoperative treatment with vincristine, bleomycin, mitomycin c, cis-platin and radiotherapy after surgery for high-risk patients with cervical carcinoma stage IB-IIA. International Journal of Gynecological Cancer 1995;5(1):40-4. [PMID: 11578451] - PubMed
Zhang 2012 {published data only}
    1. Zhang N, Zheng H, Gao Y. The effectiveness and safety of adjuvant chemotherapy in patients with intermediate-risk early stage cervical cancer after radical hysterectomy. In: International Journal of Gynecological Cancer. 14th Biennial Meeting of the International Gynecologic Cancer Society, IGCS 2012 Vancouver, BC Canada edition. Vol. 22. 2012:E800.
Zola 2003 {published data only}
    1. Zola P, Landoni F, Torri W, Buda A, Mazzola S. Randomised controlled trial of adjuvant treatment in early invasive cervical cancer [abstract]. International Journal of Gynecological Cancer 2003;13 Suppl 1:5-6.

References to ongoing studies

GOG 0263 {published data only}
    1. Ryu SY, Koh W. Radiation therapy with or without chemotherapy in patients with stage I or stage II cervical cancer who previously underwent surgery. www.ClinicalTrials.gov; NCT01101451.
Hong 2013 {published data only}
    1. Hong J-H. Cisplatin based chemoradiation v.s radiotherapy for cervical cancer and with clinically defined good prognosis. www.ClinicalTrials.gov;:NCT00846508.
NCT 00806117 {published data only}
    1. Liu J, Huang H. A multicenter trial of benefits of adding post-surgery chemotherapy for cervical cancer. www.ClinicalTrials.gov; NCT00806117.

Additional references

Adobe 2007 [Computer program]
    1. Adobe Photoshop CS3 extended (2007). Adobe. Adobe Systems Incorporated, 2007.
Altman 1995
    1. Altman DG, De Stavola BL, Love SB, Stepniewska KA. Review of survival analyses published in cancer journals. British Journal of Cancer 1995;72:511-8. - PMC - PubMed
Benedet 2003
    1. Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, et al. Carcinoma of the cervix uteri. International Journal of Gynaecology and Obstetrics 2003;83(Suppl 1):41-78. - PubMed
CCCMAC 2010
    1. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No: CD008285. [DOI: 10.1002/14651858.CD008285] - DOI - PMC - PubMed
CTCAE 4.0
    1. National Cancer Institute. National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI CTCAE v4.0). http://evs.nci.nih.gov/ftp1/CTCAE/About.html.
Curtin 1997
    1. Curtin JP, Shapiro F. Adjuvant therapy in gynecologic malignancies. Ovarian, cervical, and endometrial cancer. Surgical Oncology Clinics of North America 1997;6(4):813-30. [MEDLINE: PMID: 9309095] - PubMed
Deeks 2001
    1. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG, editors(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edition. BMJ Publication Group, 2001.
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177-88. - PubMed
EUROCARE 2014
    1. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al, EUROCARE-5 Working Group. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncology 2014;15(1):23-34. - PubMed
Ganz 1994
    1. Ganz PA. Quality of life and the patient with cancer: Individual and policy implications. Cancer 1994;74:1445. - PubMed
GLOBOCAN 2012
    1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, 2013.
Green 2005
    1. Green JA, Kirwan JJ, Tierney J, Vale CL, Symonds PR, Fresco LL, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No: CD002225. [DOI: 10.1002/14651858.CD002225.pub2] - DOI - PMC - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration 2011;(Version 5.1):www.cochrane-handbook.org.
Ho 2004
    1. Ho CM, Chien TY, Huang SH, Wu CJ, Shih BY, Chang SC. Multivariate analysis of the prognostic factors and outcomes in early cervical cancer patients undergoing radical hysterectomy. Gynecologic Oncology 2004;93(2):458-64. [MEDLINE: PMID: 15099962] - PubMed
Holtz 2002
    1. Holtz DO, Dunton C. Traditional management of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 2002;29:645-87. - PubMed
Im 2002
    1. Im SS, Monk BJ. New developments in the treatment of invasive cervical cancer. Obstetrics and Gynecology Clinics of North America 2002;29(4):659-72.. - PubMed
Kinney 1989
    1. Kinney WK, Alvarez RD, Reid GC, Schray MF, Soong SJ, Morley GW, et al. Value of adjuvant whole-pelvis irradiation after Wertheim hysterectomy for early-stage squamous carcinoma of the cervix with pelvic nodal metastasis: a matched-control study. Gynecologic Oncology 1989;34:258-62. - PubMed
Maduro 2003
    1. Maduro JH, Pras E, Willemse PH, Vries EG. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. Cancer Treatment Reviews 2003;29:471-88. - PubMed
McCullagh 1989
    1. McCullagh P, Nelder JA. Generalized Linear Models. London: Chapman and Hall, 1989.
Moher 1998
    1. Moher D, Pham D, Jones A, Cook DJ, Jadad AR, Moher M, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352:609-13. - PubMed
Monk 1994
    1. Monk BJ, Cha DS, Walker JL, Burger RA, Ramsinghani NS, Manetta A, et al. Extent of disease as an indication for pelvic radiation following radical hysterectomy and bilateral pelvic lymph node dissection in the treatment of stage IB and IIA cervical carcinoma. Gynecologic Oncology 1994;54:4-9. - PubMed
NCI 2004
    1. Surveillance EaERSP. SEER Public-Use 1973-2001. National Cancer Institute. National Cancer Institute, 2004.
Nitz 1994
    1. Nitz U, Roth SL, Mosny D. The value of adjuvant radio- or chemotherapy after primary surgical therapy of cervix cancer. 2. Adjuvant chemotherapy of cervix cancer. Der Gynäkologe 1994;27(2):95-8. [MEDLINE: PMID: 8039749] - PubMed
PAHO 2003
    1. Pan American Health Organisation. Regional Core Health Data Initiative. Epidemiological Bulletin 2003;24:14-5.
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34. - PubMed
Pecorelli 2009
    1. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. International Journal of Gynaecology and Obstetrics 2009;105(2):107-8. - PubMed
Perez 1995
    1. Perez CA, Grigsby PW, Castro Vita H, Lockett MA. Carcinoma of the uterine cervix. I. Impact of prolongation of treatment time and timing of brachytherapy on outcome of radiation therapy. International Journal of Radiation Oncology, Biology and Physics 1995;32:1275-88. - PubMed
RevMan 2011 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
SACR 2001
    1. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortalityand survival, 1977-2000. Incidence and mortality, 2000. Adelaide: Openbook Publishers, 2001.
SACR 2003
    1. South Australian Cancer Registry. Epidemiology of cancer in South Australia. Incidence, mortality and survival 1977 to 2001. Incidence and mortality 2001. Analysed by type and geographical location. Twenty-five years of data. Adelaide: South Australian Cancer Registry. Epidemiology Branch, 2001.
Schulz 1995
    1. Schulz KF, Chalmers I, Hayes RJ, Altman D. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12. - PubMed
Sloan 2002
    1. Sloan JA, Cella D, Frost M. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clinic Proceedings 2002;77:367. - PubMed
StataCorp 2005 [Computer program]
    1. College Station, TX: StataCorp LP StataCorp. Stata Statistical Software: Release 9. College Station, TX: StataCorp LP, 2005.
Thomas 1996
    1. Thomas GM. Adjuvant therapy after primary surgery for stage I-IIA carcinoma of the cervix. Journal of the National Cancer Institute Monograph 1996;21:77-86. - PubMed

References to other published versions of this review

Rosa 2005
    1. Rosa DD, Medeiros LRF, Bozzetti MC, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant chemotherapy for early stage cervix cancer. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No: CD005342. [DOI: 10.1002/14651858.CD005342] - DOI
Rosa 2009
    1. Rosa DD, Medeiros LRF, Edelweiss EI, Bozzetti MC, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Systematic Reviews 2009, Issue 3. Art. No: CD005342. [DOI: 10.1002/14651858.CD005342.pub2] - DOI - PubMed
Rosa 2012
    1. Rosa DD, Medeiros LR, Edelweiss MI, Pohlmann PR, Stein AT. Adjuvant platinum-based chemotherapy for early stage cervical cancer. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No: CD005342. [DOI: 10.1002/14651858.CD005342.pub3] - DOI - PMC - PubMed

Publication types

MeSH terms